ATE412013T1 - Anti-osteopontin-antikörper und dessen verwendung - Google Patents

Anti-osteopontin-antikörper und dessen verwendung

Info

Publication number
ATE412013T1
ATE412013T1 AT02713293T AT02713293T ATE412013T1 AT E412013 T1 ATE412013 T1 AT E412013T1 AT 02713293 T AT02713293 T AT 02713293T AT 02713293 T AT02713293 T AT 02713293T AT E412013 T1 ATE412013 T1 AT E412013T1
Authority
AT
Austria
Prior art keywords
osteopontin antibodies
osteopontin
antibodies
Prior art date
Application number
AT02713293T
Other languages
English (en)
Inventor
Toshimitsu Uede
Shigeyuki Kon
Yukihiko Saeki
Yasuyuki Yokosaki
Masaki Noda
Nobuchika Yamamoto
Original Assignee
Immuno Biological Lab Co Ltd
Astellas Pharma Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Immuno Biological Lab Co Ltd, Astellas Pharma Inc filed Critical Immuno Biological Lab Co Ltd
Application granted granted Critical
Publication of ATE412013T1 publication Critical patent/ATE412013T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2839—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the integrin superfamily
    • C07K16/2842—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the integrin superfamily against integrin beta1-subunit-containing molecules, e.g. CD29, CD49
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2839—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the integrin superfamily
    • C07K16/2848—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the integrin superfamily against integrin beta3-subunit-containing molecules, e.g. CD41, CD51, CD61
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Rheumatology (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Transplantation (AREA)
  • Pain & Pain Management (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
AT02713293T 2001-04-05 2002-04-04 Anti-osteopontin-antikörper und dessen verwendung ATE412013T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2001107578 2001-04-05
JP2001290700 2001-09-25

Publications (1)

Publication Number Publication Date
ATE412013T1 true ATE412013T1 (de) 2008-11-15

Family

ID=26613159

Family Applications (1)

Application Number Title Priority Date Filing Date
AT02713293T ATE412013T1 (de) 2001-04-05 2002-04-04 Anti-osteopontin-antikörper und dessen verwendung

Country Status (20)

Country Link
US (2) US20040234524A1 (de)
EP (2) EP1754719A3 (de)
JP (1) JP4230776B2 (de)
KR (1) KR100881900B1 (de)
CN (1) CN100469793C (de)
AR (1) AR033121A1 (de)
AT (1) ATE412013T1 (de)
AU (1) AU2002244968B2 (de)
BR (1) BR0208809A (de)
CA (1) CA2443330A1 (de)
CZ (1) CZ20032697A3 (de)
DE (1) DE60229509D1 (de)
ES (1) ES2314040T3 (de)
HU (1) HUP0401561A2 (de)
MX (1) MXPA03009052A (de)
NO (1) NO20034405L (de)
NZ (1) NZ528483A (de)
PL (1) PL366469A1 (de)
RU (1) RU2299888C2 (de)
WO (1) WO2002081522A1 (de)

Families Citing this family (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002090974A2 (de) * 2001-05-09 2002-11-14 Biovision Ag Verfahren zum nachweis einer progedienten, chronisch-demenziellen erkrankung, zugehörige peptide und nachweisreagenzien
ATE486092T1 (de) 2001-09-18 2010-11-15 Genentech Inc Zusammensetzungen und verfahren für die diagnose von tumoren
PL369446A1 (en) * 2001-09-25 2005-04-18 Immuno-Biological Laboratories Co, Ltd. Recombinant anti-osteopontin antibody and use thereof
WO2006043954A1 (en) * 2004-10-13 2006-04-27 Genentech, Inc. Method for treating tumors using anti-osteopontin antibodies
AU2003258127A1 (en) * 2002-08-06 2004-02-23 Diadexus, Inc. Compositions and methods relating to ovarian specific genes and proteins
JPWO2004103403A1 (ja) * 2003-05-23 2006-07-20 株式会社 免疫生物研究所 免疫担当細胞活性化阻害剤およびその用途
WO2005020785A2 (en) * 2003-07-15 2005-03-10 The Regents Of The University Of California Discovery of the microorganism that causes the human autoimmune disease, primary biliary cirrhosis
US7595045B2 (en) 2005-01-13 2009-09-29 Gene Techno Science Co., Ltd. Anti-α9 integrin antibody and the use thereof
KR20090024748A (ko) * 2006-05-31 2009-03-09 아스텔라스세이야쿠 가부시키가이샤 인간화 항인간 오스테오폰틴 항체
CN103272232B (zh) 2006-06-08 2018-07-24 中外制药株式会社 炎性疾病的预防或治疗药
WO2007149948A2 (en) 2006-06-20 2007-12-27 The Gov. Of The Usa As Represented By The Secretary Of The Department Of Health And Human Services Compositions and methods for diagnosis and treatment of tumors
KR101429783B1 (ko) 2006-07-12 2014-08-18 가부시키가이샤 진 테크노 사이언스 항 인간 α９ 인테그린 항체와 그 용도
US7981672B2 (en) 2006-09-11 2011-07-19 Immuno-Biological Laboratories Co., Ltd. Monoclonal antibody and use thereof
US8901280B2 (en) 2006-10-26 2014-12-02 Gene Techno Science Co., Ltd. Antibody against RGD in amino acid sequence of extracellular matrix protein and production method and use of the same
CN101293924A (zh) * 2007-04-24 2008-10-29 上海国健生物技术研究院 骨桥蛋白的功能表位、与其特异性结合的单克隆抗体及其在制备抗肿瘤转移药物中的用途
CN101293916A (zh) * 2007-04-24 2008-10-29 上海国健生物技术研究院 骨桥蛋白的功能表位、与其特异性结合的单克隆抗体及用途
KR100894265B1 (ko) * 2007-06-05 2009-04-21 재단법인서울대학교산학협력재단 골형성 촉진 펩타이드를 함유하는 주입형 골재생재
WO2009047283A2 (en) 2007-10-10 2009-04-16 Roche Diagnostics Gmbh Means and methods for monitoring myocardial infarction and its treatment
TWI548418B (zh) 2007-12-05 2016-09-11 中外製藥股份有限公司 Anti-NR10 / IL-31RA antibody and its use
JP2011509650A (ja) 2008-01-11 2011-03-31 株式会社ジーンテクノサイエンス ヒト化抗−α９インテグリン抗体及びその使用
AU2009203369B2 (en) 2008-01-11 2014-04-03 Astellas Pharma Inc. Improved humanized anti-human alpha9-integrin antibody
KR101746861B1 (ko) * 2008-04-24 2017-06-14 가부시키가이샤 진 테크노 사이언스 세포 외 기질 단백질의 아미노산 서열 ｒｇｄ에 특이적인 인간화된 항체 및 그의 용도
CA2753280C (en) 2009-02-23 2017-04-25 Gene Techno Science Co., Ltd. Anti-human .alpha.9 integrin antibody and use thereof
EP2406285B1 (de) 2009-03-10 2016-03-09 Gene Techno Science Co., Ltd. Erzeugung, expression und charakterisierung des humanisierten monoklonalen antikörpers k33n
WO2010131826A1 (ko) * 2009-05-12 2010-11-18 주식회사 이노파마스크린 오스테오폰틴 억제제 스크리닝 방법 및 그에 따른 억제제
IN2012DN01981A (de) 2009-09-24 2015-07-24 Gene Techno Science Co Ltd
JP6215056B2 (ja) 2011-03-01 2017-10-18 ノヴォ ノルディスク アー／エス 拮抗性ｄｒ３リガンド
GB2493540A (en) 2011-08-10 2013-02-13 Follicum Ab Agents for stimulating hair growth in mammals
TW201623329A (zh) 2014-06-30 2016-07-01 亞佛瑞司股份有限公司 針對骨調素截斷變異體的疫苗及單株抗體暨其用途
KR102514173B1 (ko) 2015-04-14 2023-03-27 추가이 세이야쿠 가부시키가이샤 Il-31 안타고니스트를 유효 성분으로서 함유하는 아토피성 피부염의 예방용 및/또는 치료용 의약 조성물
CN114867746A (zh) * 2019-08-09 2022-08-05 小利兰·斯坦福大学董事会 抗骨桥蛋白的治疗性抗体
CA3156713A1 (en) 2019-11-20 2021-05-27 Daisuke Kameoka Antibody-containing preparation

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US63241A (en) * 1867-03-26 Jacob green
US171358A (en) * 1875-12-21 Improvement in machines for trimming and punching roofing-slates
US63247A (en) * 1867-03-26 hbtdeick
US705842A (en) * 1901-10-25 1902-07-29 Daniel M Moroney Machine for assembling links in making chain belts.
SU490302A1 (ru) * 1973-07-06 1979-08-05 Свердловский Научно-Исследовательский Институт Способ лечени больных ревматизмом
US5459060A (en) * 1989-08-24 1995-10-17 Bioclonetics Incorporated Human monoclonal antibodies directed against the transmembrane glycoprotein (gp41) of human immunodeficiency virus-1 (HIV-1)
GB9122820D0 (en) * 1991-10-28 1991-12-11 Wellcome Found Stabilised antibodies
PT690132E (pt) * 1993-03-11 2004-04-30 Juridical Fou The Chemo Sero T Anticorpo monoclonal anti-hiv
EP0705842A2 (de) * 1994-10-06 1996-04-10 Hoechst Aktiengesellschaft Über Stimulation von Chondrozyten mit 1L-1Beta regulierte Genen
PT783893E (pt) * 1994-10-07 2012-05-24 Chugai Pharmaceutical Co Ltd Inibição do crescimento anormal das células sinoviais usando antagonistas de il-6 como componente ativo
US6414219B1 (en) * 1998-06-30 2002-07-02 Rutgers, The State University Of New Jersey Osteopontin knock-out mouse and methods of use thereof
CA2370301A1 (en) * 1999-04-15 2000-10-26 Children's Medical Center Corporation Osteopontin-derived chemotactic and inhibitory agents and uses therefor
IL145891A0 (en) * 1999-04-15 2002-07-25 Childrens Medical Center Methods and compositions for modulating an immune response
EP1269196B1 (de) * 2000-03-23 2007-11-21 Glaxo Group Limited Verfahren zum screening von inhibitoren für osteopontin
PL369446A1 (en) * 2001-09-25 2005-04-18 Immuno-Biological Laboratories Co, Ltd. Recombinant anti-osteopontin antibody and use thereof

Also Published As

Publication number Publication date
CZ20032697A3 (cs) 2004-01-14
KR20030092022A (ko) 2003-12-03
CA2443330A1 (en) 2002-10-17
EP1754719A3 (de) 2007-05-16
US20080069815A1 (en) 2008-03-20
CN100469793C (zh) 2009-03-18
RU2003132446A (ru) 2005-04-27
KR100881900B1 (ko) 2009-02-04
CN1513000A (zh) 2004-07-14
NZ528483A (en) 2008-03-28
EP1375518A4 (de) 2004-12-08
DE60229509D1 (de) 2008-12-04
EP1375518B1 (de) 2008-10-22
NO20034405D0 (no) 2003-10-02
ES2314040T3 (es) 2009-03-16
JP4230776B2 (ja) 2009-02-25
PL366469A1 (en) 2005-02-07
MXPA03009052A (es) 2004-10-15
AU2002244968B2 (en) 2007-07-26
AR033121A1 (es) 2003-12-03
NO20034405L (no) 2003-12-05
US20040234524A1 (en) 2004-11-25
EP1375518A1 (de) 2004-01-02
WO2002081522A1 (en) 2002-10-17
BR0208809A (pt) 2004-03-09
RU2299888C2 (ru) 2007-05-27
JPWO2002081522A1 (ja) 2004-07-29
EP1754719A2 (de) 2007-02-21
HUP0401561A2 (hu) 2004-11-29

Similar Documents

Publication Publication Date Title
ATE412013T1 (de) Anti-osteopontin-antikörper und dessen verwendung
ATE533508T1 (de) Cripto-blockierende antikörper und ihre verwendung
DE60238894D1 (de) Beleuchtungssystem und dessen Verwendung in Projektionssystem
NO20041225L (no) Rekombinant anti-osteopontinantistoff og anvendelse derav
ZA200305825B (en) Modified antibodies and methods of use
DE602004017614D1 (de) Antikörper gegen den insulinähnlichen wachstumfaktor-i-rezeptor und verwendungen dafür
EP1551447A4 (de) Anti-addl-antikörper und ihre verwendungen
ATE471344T1 (de) Antikörper gegen vla-1
AU2002244968A1 (en) Anti-osteopontin antibody and use thereof
EP1071458A4 (de) Humanisierter antikörper und dessen verwendungen
ATE424202T1 (de) Substituierte 2-thio-3,5-dicyano-4-phenyl-6- aminopyridine und ihre verwendung
DE60106423D1 (de) Entzündungshemmende verbindungen und ihre verwendung
AU2002340167A8 (en) Anti-hla-dr antibodies and the methods of using thereof
DE60230883D1 (de) Neue formulierungen und ihre verwendung
DE50206094D1 (de) Substituierte isoindole und ihre verwendung
EE200300569A (et) CD44v6-spetsiifilised antikehad
DE50214357D1 (de) Zahnradpaarung und deren Verwendung
DE50214244D1 (de) Klauenpolläufer und dessen herstellverfahren
DE60216376D1 (de) Verbundklebstoff und dessen Verwendung
DE50202730D1 (de) Substituierte isoindole und ihre verwendung
IL172510A0 (en) Antibodies and uses thereof
AU2003219093A8 (en) Anti-hpv-16 e7 antibodies and their use
IL166063A0 (en) Antibodies and uses thereof
DE60222252D1 (de) Acrylester und ihre verwendung
DE50300769D1 (de) Erdalkalialuminosilicatglas und verwendung

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties